We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.

Pfizer Inc. is offering about 662 million shares in Haleon Plc, representing its remaining stake in the maker of Sensodyne ...

In a notice to the London Stock Exchange, Pfizer (PFE) announced that it intends to sell, in aggregate, approximately 662M ordinary shares in ...

JPMorgan notes that Pfizer’s (PFE) decision on a potential move into Phase 3 for danuglipron, an oral GLP-1 drug, is expected in the coming ...

The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s (NYSE: PFE) Inlyta, reports The ...

Uncle Sam’s abiding ambivalence about having close ties with corporate America is getting some fresh, albeit unwelcome, clarity. Calling U.S. manufacturing capacity the “arsenal of democracy” in 1940, ...

We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

We’re in a somewhat unusual economic predicament right now. On one hand, inflation remains high (at least compared to the ...